SCHEMBL2495045

SCHEMBL2495045

O=[N+]([O-])c1cccn1[C@H]1C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 1/20 0.45
TK1 P04183 3/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ADRB1 P08588 1/20 0.44
DNMT1 P26358 1/20 0.44
ALOX12 P18054 1/20 0.42
ADRA1A P35348 1/20 0.42
PIM1 P11309 1/20 0.42
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
CSNK2A3 Q8NEV1 1/20 0.42
TK2 O00142 1/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14944711 1.00 SLC29A1 (0.45) SLC29A1TK1LMNASMN1; SMN2ADRB1
SCHEMBL14946761 1.00 SLC29A1 (0.45) SLC29A1TK1LMNASMN1; SMN2ADRB1
SCHEMBL13488842 0.82 ADK (0.35) SLC29A1TK1CYP1A2TYMSHBB
SCHEMBL2495405 0.79 TYMS (0.47) TYMS
SCHEMBL2494647 0.78 TK1 (0.51) SLC29A1TK1LMNASMN1; SMN2ADRB1
SCHEMBL13488841 0.78 TK1 (0.51) SLC29A1TK1LMNASMN1; SMN2ADRB1
SCHEMBL14946758 0.78 TK1 (0.51) SLC29A1TK1LMNASMN1; SMN2ADRB1
SCHEMBL14714996 0.78 TK1 (0.46) SLC29A1TK1LMNASMN1; SMN2ADRB1
SCHEMBL20953781 0.78 TK1 (0.51) SLC29A1TK1LMNASMN1; SMN2ADRB1
SCHEMBL14946754 0.78 TK1 (0.46) SLC29A1TK1LMNASMN1; SMN2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562255-A1 NUCLEIC ACID BASE ANALOG WITH QUENCHING CHARACTERISTICS AND FLUORESCENCE AND APPLICATION THEREOF Riken (JP) 2013-02-27 EP disclosed
EP-1970445-B1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS RIKEN (JP) 2012-09-26 EP disclosed
US-8030478-B2 Method for nucleic acid replication and novel artificial base pairs RIKEN (JP) 2011-10-04 US disclosed
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS RIKEN (JP) 2010-02-11 US disclosed
EP-1970445-A1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS Riken (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS POLM, POLL, POLRMT SLC29A1 354/4885TK1 78/4885LMNA 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.